

EAGLE PHARMACEUTICALS, INC.

Form 4

December 02, 2015

FORM 4**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
Tarriff Scott

2. Issuer Name **and** Ticker or Trading
Symbol
EAGLE PHARMACEUTICALS,
INC. [EGRX]

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

(Last) (First) (Middle)
C/O EAGLE
PHARMACEUTICALS, INC., 50
TICE BLVD., SUITE 315

3. Date of Earliest Transaction
(Month/Day/Year)
12/01/2015

☐ Director ☐ 10% Owner
☒ Officer (give title below) ☐ Other (specify below)
President and CEO

(Street)
WOODCLIFF LAKE, NJ 07677

4. If Amendment, Date Original
Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check
Applicable Line)
☒ Form filed by One Reporting Person
☐ Form filed by More than One Reporting
Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/01/2015		S ⁽¹⁾		2,806	D	\$ 86.92 (2)
Common Stock	12/01/2015		S ⁽¹⁾		4,744	D	\$ 87.85 (3)
Common Stock	12/01/2015		S ⁽¹⁾		1,500	D	\$ 88.8 (4)
Common	12/01/2015		S ⁽¹⁾		3,700	D	\$ 1,454,700

Edgar Filing: EAGLE PHARMACEUTICALS, INC. - Form 4

Stock					90.99		
					(5)		
					\$		
Common	12/01/2015	S(1)	1,300	D	91.46	1,453,400	D
Stock					(6)		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Own Follo Repor Trans (Instr
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

Tarriff Scott
C/O EAGLE PHARMACEUTICALS, INC.
50 TICE BLVD., SUITE 315
WOODCLIFF LAKE, NJ 07677

X

President and CEO

Signatures

/s/ David E. Riggs,
Attorney-in-Fact

12/02/2015

**Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Edgar Filing: EAGLE PHARMACEUTICALS, INC. - Form 4

- (1) These shares were sold pursuant to a Rule 10b5-1 trading plan dated as of June 19, 2015.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from \$86.44 to \$87.40, inclusive. The reporting person undertakes to provide to Eagle Pharmaceuticals, Inc., any security holder of Eagle

- (2) Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) and in footnotes (3)-(6).

- (3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from \$87.445 to \$88.37, inclusive.

- (4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from \$88.535 to \$89.07, inclusive.

- (5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from \$90.40 to \$91.37, inclusive.

- (6) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from \$91.43 to \$91.59, inclusive.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.